scPharmaceuticals Inc's fundamentals are relatively healthy, Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at max_target_price.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.
scPharmaceuticals Inc's Score
Industry at a Glance
Industry Ranking
99 / 174
Overall Ranking
263 / 4702
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
12.088
Target Price
+113.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
scPharmaceuticals Inc Highlights
StrengthsRisks
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Growing
The company is in a growing phase, with the latest annual income totaling USD 36.33M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 131.14.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.14M shares, decreasing 13.57% quarter-over-quarter.
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Ticker SymbolSCPH
CompanyscPharmaceuticals Inc
CEOMr. John H. Tucker
Websitehttps://www.scpharmaceuticals.com/
FAQs
What is the current price of scPharmaceuticals Inc (SCPH)?
The current price of scPharmaceuticals Inc (SCPH) is 5.670.
What is the symbol of scPharmaceuticals Inc?
The ticker symbol of scPharmaceuticals Inc is SCPH.
What is the 52-week high of scPharmaceuticals Inc?
The 52-week high of scPharmaceuticals Inc is 6.280.
What is the 52-week low of scPharmaceuticals Inc?
The 52-week low of scPharmaceuticals Inc is 1.940.
What is the market capitalization of scPharmaceuticals Inc?
The market capitalization of scPharmaceuticals Inc is 302.16M.
What is the net income of scPharmaceuticals Inc?
The net income of scPharmaceuticals Inc is -85.15M.
Is scPharmaceuticals Inc (SCPH) currently rated as Buy, Hold, or Sell?
According to analysts, scPharmaceuticals Inc (SCPH) has an overall rating of --, with a price target of 12.088.
What is the Earnings Per Share (EPS TTM) of scPharmaceuticals Inc (SCPH)?
The Earnings Per Share (EPS TTM) of scPharmaceuticals Inc (SCPH) is -1.815.